Publications Archives - Alzheon | Preserving Future Memories

20 Jun, 2024

Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using Quantitative Systems Pharmacology Model

alzheon2024-06-20T17:34:11-04:00June 20th, 2024|

20 Jun, 2024

Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’s Disease

alzheon2024-06-20T17:34:20-04:00June 20th, 2024|

27 Feb, 2024

The Single Toxin Origin of Alzheimer’s Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention

alzheon2024-06-19T16:17:21-04:00February 27th, 2024|

14 Jun, 2021

Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression

alzheon2024-08-09T11:48:15-04:00June 14th, 2021|

4 Dec, 2020

APOE ε4/ε4 homozygotes with early Alzheimer’s disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline

alzheon2024-08-09T11:39:48-04:00December 4th, 2020|

17 Aug, 2020

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid targeting drugs for Alzheimer’s disease with potential for near term approval

alzheon2024-06-19T18:00:43-04:00August 17th, 2020|

3 Jan, 2020

The path forward in Alzheimer’s disease therapeutics: Reevaluating the amyloid cascade hypothesis

alzheon2024-06-19T16:32:55-04:00January 3rd, 2020|

2 Dec, 2019

APOE4/4 Subjects with Early Alzheimer’s Disease Show Accelerated Loss of Cortical Thickness and Cognitive Decline Compared to APOE3/3 Subjects

alzheon2019-11-27T16:57:28-05:00December 2nd, 2019|

24 Oct, 2018

APOE4/4 Early to Mild AD Subjects Show High Rates of Hippocampal Atrophy and Cognitive Decline in ADNI-1 and Tramiprosate Datasets

alzheon2019-09-23T12:10:47-04:00October 24th, 2018|

24 Oct, 2018

Clinical Effects of Oral Tramiprosate in APOE4/4 Homozygotes with Mild Alzheimer’s Disease (AD): Responder Analyses of Cognitive and Functional Outcomes

alzheon2019-09-23T12:10:47-04:00October 24th, 2018|